# Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

> **NCT00810758** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** PF-04878691 3mg
- **DRUG:** PF-04878691 6mg
- **DRUG:** PF-04878691 9mg

## Key facts

- **NCT ID:** NCT00810758
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2009-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810758, "Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00810758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*